Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics
All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special meeting of shareholders
July 23, 2021 08:30 ET | Source: Acasti Pharma, Inc. Acasti Pharma, Inc. Laval, Quebec, CANADA
LAVAL, Québec, July 23, 2021 (GLOBE NEWSWIRE) Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces it will host a business update conference call on Wednesday, August 4
th at 1:00 PM ET to discuss the planned acquisition of Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases.
Best Penny Stocks to Buy in August? 4 for Your Watchlist
dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.
Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Form 8-K Acasti Pharma Inc For: Jul 23
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
and DONALD OLDS, Defendants. Plaintiff, Lauden Bisel ( Plaintiff ), by his undersigned attorneys, alleges upon personal knowledge with respect to himself, and information and belief based upon,
inter alia, the investigation of counsel as to all other allegations herein, as follows:
NATURE OF THE ACTION 1.This is an action brought by Plaintiff against Acasti Pharma, Inc. ( Acasti or the Company ), and the members of Acasti s board of directors (the Board or the Individual Defendants and together with Acasti, the Defendants ) for their violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 ( Exchange Act ), 15 U.S.C. §§ 78n(a) and 78t(a), and SEC Rule 14a-9, 17 C.F.R. § 240.14a-9, in connection with the proposed merger between Acasti Pharma U.S., Inc., a wholly-owned subsidiary of Acasti and Grace Therapeutics Inc. ( Grace ) (the Proposed Merger ).